Feldan Therapeutics closes a $12.5 million Series A financing round led by GC, with the participation of Stonebridge Ventures, a South Korean investor, Anges Québec Capital, including members of Anges Québec, and existing investors. Feldan is focused on the development of its pipeline of therapeutic applications based on the Feldan Shuttle, its proprietary peptide-based intracellular delivery technology.
The platform has been successfully used on several cell types – including human primary cells which are the center of most cell therapies – and allowed the delivery of nucleases, transcription factors, and antibodies. The Shuttle can overcome delivery obstacles in the context of therapeutic use by providing a safe and efficient approach that alleviates manipulation complexity and that is associated with low regulatory burden.
The platform has been successfully used on several cell types – including human primary cells which are the center of most cell therapies – and allowed the delivery of nucleases, transcription factors and antibodies.
Feldan Therapeutics’ mission is to develop regenerative medicine therapeutic applications based on the Feldan Shuttle platform. Feldan Therapeutics has generated a pipeline of clinical applications delineated in two distinct programs, the Natural Killer (NK) cell-based immunotherapy and intracellular antibody delivery, that take advantage of the unique characteristics of the Shuttle.
The Feldan Shuttle enables highly efficient delivery of proteins and peptides inside mammalian cells, both in vivo and ex vivo. Proceeds from the current financing round will support preclinical work that will enable the transfer of the technology to clinical trials.
“Our team is thrilled to work with investors and collaborators who share our belief that intracellular delivery of proteins is the future of medicine.” – Francois-Thomas Michaud
“Our team is thrilled to work with investors and collaborators who share our belief that intracellular delivery of proteins is the future of medicine,” says Francois-Thomas Michaud, chief executive officer and co-founder of Feldan. “We are also delighted to extend our relationship with key partners who will support us in bringing the Feldan Shuttle to clinical trial”.
GC is a long-time leader in South Korean public health and is a world-class stakeholder in the biopharmaceutical industry. This strategic investment complements the current collaboration between the GC group and Feldan in the development of NK cell-based therapeutics. “We believe that the Feldan Shuttle has the potential to accelerate the development of next-generation therapies”, says Yong Jun Huh, the chief executive officer of GC. “As a long-term strategic investor, we are very excited to make an investment in this potentially groundbreaking technology and best-in-class management team”.